目的系统评价XELOXs方案与FOLFOXs方案在治疗进展期胃癌中的疗效及不良反应。方法在万方、维普、CNKI、Pub Med数据库中检索XELOXs和FOLFOXs方案治疗进展期胃癌的前瞻性临床对照试验研究,对纳入研究进行质量评价,采用Rev Man 5.3进行Met...目的系统评价XELOXs方案与FOLFOXs方案在治疗进展期胃癌中的疗效及不良反应。方法在万方、维普、CNKI、Pub Med数据库中检索XELOXs和FOLFOXs方案治疗进展期胃癌的前瞻性临床对照试验研究,对纳入研究进行质量评价,采用Rev Man 5.3进行Meta分析。结果纳入12篇文献,共计825例患者。XELOXs组有效率较FOLFOXs组高(RR=1.18,95%CI:1.04~1.36,P=0.01);XELOXs方案胃肠道反应(RR=0.47,95%CI:0.39~0.57)、血小板减少(RR=0.64,95%CI:0.47~0.87)、腹泻(RR=0.59,95%CI:0.44~0.79)、白细胞减少(RR=0.53,95%CI:0.38~0.75)的发生率较FOLFOXs组低(P<0.05),手足综合症的发生率较FOLFOXs组高(RR=3.22,95%CI:0.90~11.51;P<0.00001)。XELOXs组不同累计治疗量间的疗效差异无统计学意义(P=0.125);高计量组神经毒性(P=0.002)、白细胞减少(P=0.020)、血小板较少(P=0.000)发生率高于其它两组。结论在治疗进展期胃癌中,XELOXs方案疗效优于FOLFOXs方案;XELOXs方案不同累计治疗剂量间疗效无差异,且不良反应发生率随剂量增高而增高。展开更多
BACKGROUND Owing to the absence of specific symptoms in early-stage gastric cancer,most patients are diagnosed at intermediate or advanced stages.As a result,treatment often shifts from surgery to other therapies,with...BACKGROUND Owing to the absence of specific symptoms in early-stage gastric cancer,most patients are diagnosed at intermediate or advanced stages.As a result,treatment often shifts from surgery to other therapies,with chemotherapy and targeted therapies being the primary options for advanced gastric cancer treatment.A total of 116 patients with advanced gastric cancer,admitted from January 2021 to December 2023,were selected and divided into two groups of 58 each using the random number table method.The control group received FOLFOX4 chemothe-rapy(oxaliplatin+calcium+folinate+5-fluorouracil)combined with intravenous sindilizumab.The observation group received the same treatment as the control group,supplemented by oral administration of Senqi Shiyiwei granules.Both groups underwent treatment cycles of 3 weeks,with a minimum of two cycles.The therapeutic efficacy,immune mechanisms,and treatment-related toxicity and side effects were compared between the groups.The objective remission rate in the observation group(55.17%)was higher than that of the control group(36.21%)(P<0.05).After two treatment cycle,CD3+,CD4+,and CD4+/CD8+levels were higher in the observation group compared to the control group,while CD8+,regulatory T cells,and natural killer cells were lower(P<0.05).Additionally,the incidence of leukopenia,nausea,and vomiting was lower in observed group(P<0.05).No significant differences were observed in the incidence of other adverse reactions(P>0.05).CONCLUSION Adjuvant therapy with Shenqixian granules may enhance the efficacy of simudizumab combined with FOLFOX4 chemotherapy in advanced gastric cancer and the immune function by increasing immune cell counts,making it a valuable option in clinical treatment.展开更多
BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for imp...BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.展开更多
文摘目的系统评价XELOXs方案与FOLFOXs方案在治疗进展期胃癌中的疗效及不良反应。方法在万方、维普、CNKI、Pub Med数据库中检索XELOXs和FOLFOXs方案治疗进展期胃癌的前瞻性临床对照试验研究,对纳入研究进行质量评价,采用Rev Man 5.3进行Meta分析。结果纳入12篇文献,共计825例患者。XELOXs组有效率较FOLFOXs组高(RR=1.18,95%CI:1.04~1.36,P=0.01);XELOXs方案胃肠道反应(RR=0.47,95%CI:0.39~0.57)、血小板减少(RR=0.64,95%CI:0.47~0.87)、腹泻(RR=0.59,95%CI:0.44~0.79)、白细胞减少(RR=0.53,95%CI:0.38~0.75)的发生率较FOLFOXs组低(P<0.05),手足综合症的发生率较FOLFOXs组高(RR=3.22,95%CI:0.90~11.51;P<0.00001)。XELOXs组不同累计治疗量间的疗效差异无统计学意义(P=0.125);高计量组神经毒性(P=0.002)、白细胞减少(P=0.020)、血小板较少(P=0.000)发生率高于其它两组。结论在治疗进展期胃癌中,XELOXs方案疗效优于FOLFOXs方案;XELOXs方案不同累计治疗剂量间疗效无差异,且不良反应发生率随剂量增高而增高。
文摘BACKGROUND Owing to the absence of specific symptoms in early-stage gastric cancer,most patients are diagnosed at intermediate or advanced stages.As a result,treatment often shifts from surgery to other therapies,with chemotherapy and targeted therapies being the primary options for advanced gastric cancer treatment.A total of 116 patients with advanced gastric cancer,admitted from January 2021 to December 2023,were selected and divided into two groups of 58 each using the random number table method.The control group received FOLFOX4 chemothe-rapy(oxaliplatin+calcium+folinate+5-fluorouracil)combined with intravenous sindilizumab.The observation group received the same treatment as the control group,supplemented by oral administration of Senqi Shiyiwei granules.Both groups underwent treatment cycles of 3 weeks,with a minimum of two cycles.The therapeutic efficacy,immune mechanisms,and treatment-related toxicity and side effects were compared between the groups.The objective remission rate in the observation group(55.17%)was higher than that of the control group(36.21%)(P<0.05).After two treatment cycle,CD3+,CD4+,and CD4+/CD8+levels were higher in the observation group compared to the control group,while CD8+,regulatory T cells,and natural killer cells were lower(P<0.05).Additionally,the incidence of leukopenia,nausea,and vomiting was lower in observed group(P<0.05).No significant differences were observed in the incidence of other adverse reactions(P>0.05).CONCLUSION Adjuvant therapy with Shenqixian granules may enhance the efficacy of simudizumab combined with FOLFOX4 chemotherapy in advanced gastric cancer and the immune function by increasing immune cell counts,making it a valuable option in clinical treatment.
文摘BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.
